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Five high-grade (3 grade III and 2 grade IV) astrocytoma tumour cell populations were treated with a
preparation of Human Leukocyte Interferon either in monolayer cell culture or as multicellular spheroids in
vitro or as xenografts growing in immune-deprived mice in vivo. A moderate and transient sensitivity was seen
in one grade III tumour when tested in both of the in vitro assays, but no inhibition of growth was seen in
vivo. Two tumours which were apparently resistant to Interferon treatment responded to orthodox
chemotherapy. When used in conjunction with BCNU, Interferon was not effective in prolonging delay in
tumour growth. It is concluded that Interferon is unlikely to be an effective agent in the treatment of
malignant brain tumours.
The prognosis for patients with grade III-IV
astrocytomas is poor. Median survival for patients
with such following major surgery and radical
radiotherapy with or without chemotherapy
remains of the order of 6 months and survival
beyond 3 years is rare (see reviews by Bloom, 1982;
Walker & Gehan, 1976). There is, therefore,
considerable interest in finding more effective
therapies for these tumours which may also prove
of value for other intra-cranial gliomas in adults
and children.
Recent results suggest that treatment of some
tumour types with various preparations of
Interferon (IFN) might result in occasional clinical
success (Gutterman et al., 1980). Experimental
support for this suggestion derives, in part, from
the observations that IFNs were found capable of
inhibiting the in vitro growth of a wide variety of
both normal and malignant cell types (Balkwill &
Oliver, 1977). They have also been shown to
regulate the immune system (Gresser, 1977) and to
induce differentiated characteristics in some nervous
system tumour cell cultures (Bal de Kier Joffe et
al., 1979).
The effects of IFN on the in vivo growth of both
transplantable rodent tumours and human tumour
xenografts are varied, in that IFN treatment can
either inhibit tumour incidence or growth in some
rodent tumours, or have no effect at all in others
(for review see Priestman, 1979). In the case of
human tumour xenografts, IFN treatment has been
found to increase the period between implantation
and perceptible growth in two out of three human
breast cancer xenografts in Nude mice (Balkwill et
al., 1980). De Clerq et al. (1978) found that IFN
had no effect on the growth of human tumour
xenografts derived from a fibrosarcoma and a
melanoma.
With these results in mind, we have examined the
effects of Human Leukocyte Interferon (HLI) on a
number of human gliomas, using three systems that
we have developed in our co-operative studies of
glioma chemosensitivity. In this report, we present
our results on the effects of one preparation of HLI
on the growth of high-grade astrocytoma cell
populations, both in vitro and in vivo. Results of
treating a number of these tumours with certain
cytotoxic agents, alone or in combination with
HLI, are also presented as an attempt to determine
the possibility that HLI might be effective against
minimal residual disease.
Materials and methods
Media and reagentsfor cell culture
Cell cultures were maintained and the HLI assays
were carried out in Ham's FIO (Flow Laboratories,
Irvine, Scotland) medium supplemented with 10%
heat-inactivated foetal calf serum (HIFCS),
buffered with 20mM HEPES and containing
antibiotics (Morgan et al., 1983).
Initiation ofmonolayer cultures
Biopsies from a range of human brain tumours
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Table I Tumours used
Histology Tested
Tumour (Astrocytoma) Site2 Sex Age as:
14/81 grade 11 R. temp par occip M 36 M3
15/81 grade IV1 L. temp par F 52 M3
478 grade IIII L. temp M 61 X
496 grade IIF L. fronto par M 65 M3, S4
508 grade IVI R. temp par F 58 M3, X
'Kernohan-Sayre grading.
2R=right, L=left, par=parietal, temp=temporal, occip=occipital,
post=posterior.
3all monolayers (M) tested as secondary cultures.
4all spheroids (S) derived from tumour biopsies or xenografts (X)
(Darling, et al., 1982).
(Table I) were taken at the time of surgical
resection and from two xenografted gliomas
growing in immune-deprived mice during routine
passage. Collagenase digests were performed and
the resulting cell suspensions dispensed into 25cm2
culture flasks as previously described (Thomas et
al., 1979).
Preparation ofmulticellular spheroids
Spheroids were derived from a xenografted human
grade III astrocytoma (Table I). A modification of
the method of Yuhas et al., (1977) was used
(Darling et al., 1983)
Animals
The mice used in these experiments were from the
inbred CBA/Ca strain, bred and maintained at the
ChesterBeattyResearchLaboratories.TheywereT-cell
deprived and implanted with tumour as described
previously (Bradley et al., 1978).
Transplantation oftumour in mice
Tumours that were growing in immune-deprived
mice were dissected when they had grown to
approximately 2cm3, trimmed of obvious fascial
tissue and cut into about 8mm3 pieces.
Anaesthetised mice were each implanted with two
pieces of tumour.
Drugs
(a) Interferon One batch of clinical grade HLI
was used. It was obtained from Interferonlab,
Denmark (batch code 9236901), with a stated
activity of 5.98x106Uml-1. It was supplied as a
frozen liquid and was diluted with sterile PBS
containing 1% heat inactivated foetal calf serum
(HIFCS), to a final concentration 2 x 10 Uml-1.
The HLI titre was confirmed by 3 independent
virus neutralisation assays. One ml aliquots of
diluted HLI were stored frozen at -20°C until
used. For in vitro assays, the HLI was further
diluted in Ham's FlO containing 10% HIFCS and
antibiotics. Concentrations of HLI used in these
assays ranged from 1000 to 0.01 Uml1, diluted in
10-fold steps.
(b) Cytotoxic drugs In animal experiments the
drugs used were:
(i) BCNU, which was supplied as a reference
standard. It was dissolved in ethanol, diluted
with saline to 10% v/v and was administered
as a single i.p. injection at a maximum
tolerated dose of 10mgKg- .
(ii) Procarbazine (Natulan) was supplied as a pure
preparation of Procarbazine Hydrochloride. It
was administered using the i.p. route, as 5
daily doses of 100mgKg-1, dissolved in sterile
saline.
Monolayer assay ofIFN activity
The method used to estimate HLI sensitivity of
monolayer cell cultures was that of Morgan et al.
(1983). Cell cultures in exponential growth were
treated with HLI at various dilutions in replicate
micro-titration plates. Residual viability was
assessed by [35S]-methionine incorporation and
autofluorography in situ at 2 time points. One of
the replicate plates was processed for
autofluorography immediately following IFN
treatment, whilst the second plate was washed free
of IFN and re-fed with fresh growth medium.
Culture was continued for a further 2-3 cell
population-doubling times. At this point the second
plate was processed for autofluorography. In this
way it proves possible to examine the reversibility
ofdrug treatment.HUMAN BRAIN TUMOURS AND INTERFERON 821
Multicellular spheroid assay ofIFN activity
Single spheroids were removed using a sterile finely-
drawn Pasteur pipette and transferred to agar-
coated wells of a micro-titration plate. Each well
was then fed with 0.1-0.2ml of fresh growth
medium. Ten spheroids were used in each of the
control and treatment groups. After 1-2 days
growth, the volume of each spheroid was
determined by measuring the two perpendicular
diameters and calculating the volume using the
formula V=- x (mean diameter)3. 6
Medium was then removed from test wells and
replaced with the appropriate volume of HLI
dilution in growth medium. After 24-48h
incubation, the HLI was removed and replaced
with fresh growth medium. The volumes of the
spheroids were determined every 24h, up to 11
days post-treatment and growth curves constructed.
Spheroid volume doubling times (TD) were
calculated and HLI sensitivity determined by
calculating a growth delay index (GDI) from the
following formula (Nowak et al., 1978).
GDI =TDtreated tumours -TDuntreated tumours
TDuntreated tumours
Xenograft assay ofIFN sensitivity
HLI at a concentration of 2x 15UmlP1, or
diluent (1% HIFCS in PBS), was administered by
daily s.c. injections of 0.1 ml to the inguinal region
(Balkwill et al., 1980). Treatment was started as
soon as individual mice were determined to have
palpably growing tumours, - 2mm in diameter.
Volumes of tumours were determined by measuring
3 perpendicular axes of each tumour and
substituting in the equation:
V=- x(d1 xd2 x d3) 6
Growth curves were constructed and GDI figures
obtained by using the same method as for the
spheroids.
Results
In vitro studies
Monolayer cultures Cell cultures derived from two
high-grade astrocytomas obtained during surgical
biopsy were treated with IFN and their sensitivity
to this drug was established at the 2 time-points
defined in the Methods section. Tumour 14/81, the
grade III astrocytoma, had a maximum inhibition
of protein synthesis of 48% of control values
immediately after IFN treatment and 42% after
28h recovery in fresh medium. The grade IV
astrocytoma, 15/81, initially showed a slight
stimulation of protein synthesis compared with
control cultures, which was lost after recovery in
fresh medium. Two cell cultures derived from
astrocytoma xenografts were also examined. For
tumour 496, the maximum inhibition of protein
synthesis was 70% at an IFN concentration of
1000Uml-P immediately after drug removal and
the ID50 (concentration of drug which inhibited
protein synthesis by 50%) was 30UmlP1. However,
after recovery, the maximum inhibition at
1000Uml-1 remained unchanged at 70Uml-' but
the ID50 had increased by over 10-fold, to
340Uml 1. Tumour 508, on the other hand,
appeared more resistant to treatment with HLI.
Immediately after IFN removal, the maximum
inhibition at 1000Uml1 was 27% and after
recovery in fresh medium there was no measurable
inhibition of protein synthesis. Table II shows the
ID50 values for all the monolayer cell cultures. It
should be stressed that for only one tumour was it
possible to derive ID50 values at the IFN
concentrations used.
Table H ID5O Results obtained from treating monolayer
cell cultures with human leukocyte Interferon.
Units HLIml 1
ID50 ID50
Tumour After HLI Exposure After Recovery
14/81 >1000 >1000
15/81 >1000 >1000
496 30 340
508 >1000 >1000
Multicellular spheroids One glioma, derived from a
xenograft-maintained grade III astrocytoma was
marginally sensitive to HLI over the 3 doses
studied. Following exposure for 48h to HLI, there
was a transient delay in growth which occurred 5
days following the replacement of medium
containing HLI, with medium alone. The Median
Growth Delay Indicies (MGDI), shown in Table III
illustrate that the maximum number of tumour
volume doubling times saved was only 1.7. This
occurred in the multicellular spheroids that were
exposed to 102UmlP- HLI.
In vivo studies
The experimental design, including information on
the number of tumours used in these studies is
indicated in Table IV.822 N.J. BRADLEY et al.
Table III Growth delay indices obtained from treating multicellular spheroids in
vitro and xenografts in vivo with IFN and chemotherapy.
GDI
Tumour HLI Procarb BCNU BCNU+HLI TDUC
(i) in vitro-spheroids
496-IOUml-1 1.29 ND ND ND 6.57
496-102Uml-1 1.70 ND ND ND 6.57
496-103Uml-' 1.08 ND ND ND 6.57
(ii) in vivo-xenografts
478 0.2 1.75 0.1 0.1 4.1
508 0 ND 8.7 9.6 5.6
TD), =Median tumour volume doubling times of untreated control tumours.
ND=not determined.
Table IV Xenografts used in in vivo experiments.
BCNU+
Untreated Diluent controls Interferon BCNU Interferon Procarbazine
controls 1% FCS in PBS 2x 104 U/day 1Omgkg-1 JOmgkg-1+2x 04 U 100mgkg-1qdx 5
No. of No. of No. of No. of No. of No. of No. of No. of No. of No. of No. of No. of
mice tumours mice twnours mice tumours mice tumours mice tumours mice tumours
478 Astro III 5 10 5 10 6 12 5 10 5 10 5 10
508 Astro IV 6 12 6 12 6 10 5 7 7 12 ND
ND=Not done.
Tumour 478 (Chemo-resistant grade III astro-
cytoma) There was perceptible growth of all
tumours 9 days following implantation. Treatment
was started on the 10th day. Animals were injected
with either diluent (PBS-HIFCS) or HLI every day.
The animals were killed 23 days following the start
of treatment, at which time the tumours had
reached a median volume of 572mm3. Further
groups of mice were treated with BCNU, BCNU +
HLI or Procarbazine respectively.
Neither HLI nor BCNU alone had any
observable inhibitory effect on the growth of this
tumour. Similarly, mice that were treated with
BCNU + HLI in combination showed no delay in
tumour growth. However, treatment with
Procarbazine resulted in a transient regression of
tumours, the median growth delay index being 1.75
(Table III). There was no inter-group variation of
the animals' weights, which were recorded on
alternate days during the course of the experiment.
Similarly, no signs of fever could be detected
amongst any of the mice treated with HLI, as
assessed by the comparison of rectal temperatures,
again measured on alternate days.
Tumour 508 (Chemo-sensitive grade IV astro-
cytoma) As before, mice were treated with diluent
or HLI on a daily basis, which was administered as
soon as the tumours were palpably growing. No
appreciable delay in growth was observed following
either of these two treatments. A single injection of
BCNU, however, resulted in complete regression of
6/7 tumours in this group. The remaining tumour
subsequently regrew 49 days following the BCNU
injection (GDI=8.7). Of the 12 tumours exposed to
both BCNU and HLI, 10 regressed completely and
2 tumours subsequently regrew, 1 recurring 51 days
and the other 68 days following the start of therapy
(Mean GDI=9.6). These results are shown in Table
III. The recurrent tumours derived from from 2
separate animals. The mice, which were again
weighed throughout the course of the experiment
and had their rectal temperatures measured as
before, showed no indications of inter-group
variation of these parameters.
Discussion
Interferon, when used over a wide range of doses,HUMAN BRAIN TUMOURS AND INTERFERON 823
had only a modest effect on the protein synthetic of
one of four human glioma cell cultures and on the
the growth of multi-cellular spheroids derived from
a xenografted human glioma. There was a general
pattern of initial modest sensitivity observed in
monolayer cell cultures which appeared to be
rapidly lost within 24-72 h (1-3 cell generations)
incubation in fresh medium. The initial suppression
of protein synthesis in glioma cells is interesting as,
although the synthesis of specific inducible proteins
can be inhibited by IFN, a generalised suppression
is not a usual feature (Taylor-Papadimitriou, 1980).
It has been suggested that the inhibition of specific
proteins is in some way responsible for the anti-
proliferative effect of IFNs. In glioma cells the
synthesis of a specific protein may be affected
which causes a generalised inhibition of growth. In
any event our results indicate that this "block", if it
exists in our systems, seems to be rapidly reversible
upon incubation in fresh medium. This latter aspect
is in agreement with Kuwata et al. (1976) who
reported that although HLI was able to inhibit the
growth of two transformed human embryonic cell
lines, recovery in fresh medium was possible. From
previous studies on the patterns of response to
cytotoxic drugs in vitro (Thomas et al., 1982:
Darling & Thomas in preparation), it is apparent
that if a culture derived from a patient's tumour
rapidly loses sensitivity to a drug upon recovery in
fresh medium after drug treatment (Morgan et al.,
1983) it is an indication that the patient's tumour
will not respond to that drug clinically.
The binding and entry of IFN to cells has been
suggested as one mechanism for the apparent
resistance of certain cell cultures (Kuwata et al.,
1976; Berman & Vilcek, 1974) whilst other authors
have suggested that the proliferative state of cells in
culture may be an important factor which controls
IFN sensitivity (Horoszewicz et al., 1979: Creasey
et al., 1980). In our monolayer experiments, the
cells were treated whilst in exponential growth,
which may partially account for their resistance to
IFN. On the other hand cells growing as spheroids
are not all in cycle (Sutherland & Durand 1976)
and hence, possibly, the cycle-specific effects of
IFN should be more noticeable in this model
system, but this was not the case. Indeed, if non-
cycling cells were much more sensitive than cycling
cells, then tumours growing as xenografts should
respond.
HLI had no observable effect on the growth of
two gliomas growing as xenografts in immune-
deprived mice, either when administered alone or in
conjunction with BCNU.
The route of injection (s.c.) and dosage may not
have been optimal. However, Balkwill et al. (1980)
using the same dosage, route of administration and
schedule reported significant anti-tumour activity of
Namalwa Human Lymphoblastoid IFN against 2
of 3 human breast tumour xenografts growing in
nu/nu mice. However, Balkwill et al., started
treatment on the day of tumour implantation rather
than starting treatment when tumours were
established; it may be that IFN treatment affects
the stromal/tumour cell interaction and subsequent
growth during the vascularisation of a freshly
transplanted tumour. In any event, the dosage of
IFN used in not only the in vivo, but also the in
vitro experiments, was well in excess of that used in
clinical practice.
As the major variable might be within the
different types of IFN, the question of IFN-
specificity must be considered. Although both
Lymphoblastoid and Leukocyte IFNs are thought
to be structurally-related and not to be species-
specific, there is a suggestion that HLI is tissue-
specific. When HLI and Human Fibroblast IF
(HFI) were tested against osteosarcoma and
lymphoblastoid cell lines, the effect of the HLI was
more marked against the lymphoid line and the
HFI most marked against the osteosarcoma line
(Einhorn & Strander, 1977). If IFNs are restricted
in their effectiveness even within mesenchyme-
derived cell types, then HLI would not be presumed
to be effective against neuroglial tumours which are
derived from ectoderm. Indeed, preliminary results
indicate that HFI is unit for unit more effective
than HLI in inhibiting protein synthesis in glioma
cell cultures (Darling, unpublished observations).
For both the in vitro and in vivo experiments, it is
possible that the tumours examined could have
been uniformly resistant to drug therapy. When the
xenografts were treated in vivo with either
Procarbazine or BCNU, responses were seen, which
in the case of the grade IV-derived tumour resulted
in complete regression of the majority of the
tumours. These results are in accordance with our
wider observations on the drug-sensitivity of human
glioma xenografts (observations to be published).
The inclusion of HLI into the chemotherapy
schedule had no observable effect. With regard to
the grade IV tumour, it might be supposed that the
effects of HLI could have manifested themselves in
assisting the killing of the relatively small number
of cells remaining after BCNU therapy. The fact
that two tumours treated with this combination
subsequently regrew suggests that this does not
occur.
Interferon not only has anti-proliferative effects,
but may also have an effect on cells of the immune
system. Gresser and his colleagues (1972) have
shown that L1210 cells although apparently
resistant to the anti-cellular effects of IFN in vitro,
were inhibited in vivo. Further work has established
that this may be due to a regulation ofeffector cells
in the immune system (Lindahl et al., 1972). Indeed824 N.J. BRADLEY et al.
a recent series of reports (Ikic et al., 1981a,b,c)
describes substantial benefits obtained by treating a
variety of human tumours with intra-tumoural
injections of HLI. The suggestion is that HLI
administration by this route is indirectly effective
by inducing reactivity of tumour stroma
(mesenchyme) and regional lymph nodes. If the
action of HLI in vivo is via the stromal elements,
this would need to be examined further, particularly
in the light of a recent report (Salford et al., 1981),
which describes tumour encapsulation and a
decrease in histological grading following intra-
tumoural injections of HLI into high-grade cerebral
gliomas.
Recent reports of clinical experience with this
agent seem to confirm the lack of clinical benefits.
Sawada et al. (1982), using systemically
administered IFN failed to demonstrate an
unequivocal effect in glioma patients. This may, of
course, be due to incomplete penetration into the
brain tumour. This area has not been extensively
studied. It is apparent that IFN does not pass the
intact blood/CSF barrier in significant amounts
(Jordan et al., 1974) and there is no information as
to the penetration of IFN through the partially
disrupted blood/brain barrier associated with the
growth of a malignant glioma. Even if IFN is
effective by direct modulation of the systemic
immune-response, this immunological advantage
may not reach the brain if it retains partial
immunological privilege (Darling et al., 1981).
The results obtained from this series of
experiments designed to examine the possible
benefits of HLI in glioma therapy, do not suggest
that this drug, given systemically, even in
combination with cytotoxic drugs cytotoxic drugs
has any appreciable anti-proliferative effects. Unless
any substantial effect on the tumour stroma or
immune response can be demonstrated it is unlikely
that IFN will have any significant role to play in
the clinical treatment of gliomas.
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